Gemcitabine Hydrochloride
Who holds supplier records for Gemcitabine Hydrochloride? 20 organisations hold a current record for Gemcitabine Hydrochloride: an active US FDA Type II Drug Master File or a CEP. A further 10 organisations have only historical (inactive) DMF filings. 15 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (12), China (4), Netherlands (1), Spain (1) and 2 other countries (2).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Gemcitabine Hydrochloride: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/gemcitabine-hydrochloride
Reading the evidence
- 20 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
12 of the 20 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 9 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (20)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Gemcitabine Hydrochloride. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Intas Pharmaceuticals Ltd.IndiaCEP Company GMP cert on recordActive DMF 22748, 36573 · latest filing Dec 2021
- SHILPA PHARMA LIFESCIENCES LTDIndiaCEPActive DMF 31892, 24136 · latest filing Jul 2017
- TAPI NL BVNetherlandsCEPActive DMF 27402, 20979 · latest filing Feb 2014
- ARCH PHARMALABS LTDIndiaActive DMF 23633, 23801 · latest filing May 2010
- Emcure Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 23339, 27617 · latest filing Oct 2013
- Dr. Reddy's Laboratories Ltd.IndiaCEP Company GMP cert on recordActive DMF 18857 · latest filing Oct 2005
- FARMHISPANIA SASpainCEPActive DMF 40133 · latest filing Jul 2024
- Hetero Labs LimitedIndiaCEP Company GMP cert on recordActive DMF 22229 · latest filing Nov 2008
- Jiangsu Hansoh Pharmaceutical Group Company LimitedChinaCEP Company GMP cert on recordActive DMF 18810, 31481 · latest filing Mar 2017
- Laurus Labs LimitedIndiaCEP Company GMP cert on recordActive DMF 22800 · latest filing May 2009
- RAVI BIOLIFE PRIVATE LTDIndiaCEPActive DMF 39824 · latest filing Apr 2024
- SCINOPHARM TAIWAN LTDTaiwanCEPActive DMF 19053 · latest filing Dec 2005
- Sun Pharmaceutical Industries LimitedIndiaCEP Company GMP cert on recordActive DMF 19427 · latest filing May 2006
- Gland Chemicals Private LimitedIndiaActive DMF 25938 · latest filing Jun 2012
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 27043 · latest filing May 2013
- YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTDChinaActive DMF 31117 · latest filing Nov 2018
- United StatesCEP
- FRESENIUS KABI ONCOLOGY LTDIndiaCEP Company GMP cert on recordInactive DMF 21399 · latest filing Apr 2008
- GRAND WUYAO (JIANGSU) PHARMACEUTICAL CO. LTD.ChinaCEPValid CEP holder (EDQM); not necessarily the manufacturer
- FUAN PHARMACEUTICAL GROUP NINGBO TEAM PHARMACEUTICAL CO., LTD.ChinaCEPValid CEP holder (EDQM); not necessarily the manufacturer
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (15)
Certificates of Suitability on the EDQM register for Gemcitabine Hydrochloride, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 29 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| GRAND WUYAO (JIANGSU) PHARMACEUTICAL CO. LTD. Lianyungang | CN | CEP 2025-157 - Rev 00 Gemcitabine hydrochloride | Jun 2026 | — |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai | IN | CEP 2007-021 - Rev 03 Gemcitabine hydrochloride | Mar 2026 | — |
| HETERO LABS LIMITED Hyderabad | IN | CEP 2022-499 - Rev 01 Gemcitabine hydrochloride, GA process | Feb 2026 | — |
| INTAS PHARMACEUTICALS LIMITED Ahmedabad | IN | CEP 2022-092 - Rev 03 Gemcitabine hydrochloride, Process III | Feb 2026 | — |
| RAVI BIOLIFE PRIVATE LIMITED Mumbai | IN | CEP 2023-229 - Rev 01 Gemcitabine hydrochloride | Dec 2025 | — |
| LAURUS LABS LIMITED Hyderabad | IN | CEP 2025-445 - Rev 00 Gemcitabine hydrochloride, Process-3 | Nov 2025 | — |
| SHILPA PHARMA LIFESCIENCES LIMITED Raichur | IN | CEP 2006-222 - Rev 02 Gemcitabine hydrochloride | Jul 2025 | — |
| FARMHISPANIA S.A. Montmeló | ES | CEP 2024-203 - Rev 00 Gemcitabine hydrochloride | Jun 2025 | Inspected May 2023 Spain, outside 3-year window |
| TAPI NL B.V. Amsterdam | NL | CEP 2008-161 - Rev 03 Gemcitabine hydrochloride | May 2025 | — |
| FRESENIUS KABI ONCOLOGY LIMITED Kalyani | IN | CEP 2008-131 - Rev 05 Gemcitabine hydrochloride | Nov 2024 | — |
| SCINOPHARM TAIWAN LTD. Shan-Hua | TW | CEP 2006-272 - Rev 07 Gemcitabine hydrochloride | Sept 2024 | — |
| JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. Lianyungang City | CN | CEP 2017-076 - Rev 01 Gemcitabine hydrochloride | Sept 2024 | — |
| DR. REDDY'S LABORATORIES LIMITED Hyderabad | IN | R1-CEP 2007-075 - Rev 06 Gemcitabine hydrochloride | Jun 2021 | — |
| FUAN PHARMACEUTICAL GROUP NINGBO TEAM PHARMACEUTICAL CO., LTD. Ningbo | CN | R1-CEP 2009-042 - Rev 01 Gemcitabine hydrochloride | Oct 2015 | — |
| Eli Lilly And Company Indianapolis | US | R1-CEP 2007-063 - Rev 00 Gemcitabine hydrochloride | Nov 2014 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (10)
Organisations whose Type II DMFs for Gemcitabine Hydrochloride are no longer active. These show a past filing, not current supply.
Show all 10 historical records
- DISHMAN PHARMACEUTICALS AND CHEMICALS LTDInactive DMF 27649 · filed Oct 2013
- India · Inactive DMF 27442 · filed Sept 2013
- China · Inactive DMF 24893 · filed Apr 2011
- JARI PHARMACEUTICAL CO LTDInactive DMF 24341 · filed Oct 2010
- Taiwan · Inactive DMF 24278 · filed Oct 2010
- MYLAN LABORATORIES LTDInactive DMF 23833 · filed May 2010
- Italy · Inactive DMF 23516 · filed Feb 2010
- India · Inactive DMF 23433 · filed Jan 2010
- Italy · Inactive DMF 22199 · filed Oct 2008
- BENZOCHEM LIFESCIENCES PVT LTDInactive DMF 21274 · filed Jan 2008
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Gemcitabine Hydrochloride is a nucleoside analog used as chemotherapy. It is primarily utilized in the treatment of various carcinomas, including non-small cell lung cancer and pancreatic cancer.
Chemical identity
- IUPAC name
- 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrochloride
- Canonical SMILES
- C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F.Cl
- InChIKey
- OKKDEIYWILRZIA-OSZBKLCCSA-N
- Synonyms
- Gemzar API, avgemsi, gemcitabine (as hydrochloride), gemcitabine hcl, gemzar, infugem, inlexzo, ly-188011 hydrochloride, ly188011 hydrochloride
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Nucleoside Metabolic Inhibitor
- Mechanism of action
- Nucleic Acid Synthesis Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Gemcitabine Hydrochloride?
20 organisations hold an active US FDA Type II Drug Master File or a CEP for Gemcitabine Hydrochloride: Intas Pharmaceuticals Ltd. (India), SHILPA PHARMA LIFESCIENCES LTD (India), TAPI NL BV (Netherlands), ARCH PHARMALABS LTD (India), Emcure Pharmaceuticals Limited (India), Dr. Reddy's Laboratories Ltd. (India), FARMHISPANIA SA (Spain) and Hetero Labs Limited (India), and 12 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Gemcitabine Hydrochloride Drug Master Files are active?
Intas Pharmaceuticals Ltd. (DMF 22748, 36573), SHILPA PHARMA LIFESCIENCES LTD (DMF 31892, 24136), TAPI NL BV (DMF 27402, 20979), ARCH PHARMALABS LTD (DMF 23633, 23801), Emcure Pharmaceuticals Limited (DMF 23339, 27617), Dr. Reddy's Laboratories Ltd. (DMF 18857), FARMHISPANIA SA (DMF 40133) and Hetero Labs Limited (DMF 22229) and 8 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Gemcitabine Hydrochloride records mean?
10 organisations have only inactive Type II DMFs for Gemcitabine Hydrochloride. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Gemcitabine Hydrochloride have a European Certificate of Suitability?
Yes. 15 organisations hold a valid CEP for Gemcitabine Hydrochloride on the EDQM register, including GRAND WUYAO (JIANGSU) PHARMACEUTICAL CO. LTD. Lianyungang (CN), SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai (IN), HETERO LABS LIMITED Hyderabad (IN), INTAS PHARMACEUTICALS LIMITED Ahmedabad (IN), RAVI BIOLIFE PRIVATE LIMITED Mumbai (IN) and LAURUS LABS LIMITED Hyderabad (IN) and 9 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Gemcitabine Hydrochloride supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Gemcitabine Hydrochloride?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.